-
April 09, 2013
Patients with advanced skin cancer living in Scotland will be given National Health Service access to the first new medicine for the disease to be licensed in the UK in more than 30 years.
Full story
-
March 05, 2013
Patients with diabetes in the UK can now get access to a new treatment option following the roll out of Novo Nordisk's ultra-long-acting insulin Tresiba in the country, marking its first launch in Europe.
Full story
-
February 12, 2013
Novo Nordisk has suffered a huge blow after US regulators refused to approve its new insulin Tresiba.
Full story
-
November 09, 2012
Shares in Novo Nordisk have soared this morning after an FDA panel recommended approval of Tresiba and Ryzodeq, despite expressing concerns over possible cardiovascular risk of the ultra long-acting insulins
Full story
-
November 07, 2012
Shares in Danish drugmaker Novo Nordisk slipped after it emerged that US health officials remain concerned over the heart safety of its diabetes drug Tresiba
Full story
-
October 01, 2012
Novo Nordisk has been granted a first approval for its ultra long-acting insulin degludec, in Japan, and has discontinued development of a Phase III haemophilia drug
Full story